Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII
- 18 January 2011
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 108 (5), 2082-2087
- https://doi.org/10.1073/pnas.1015571108
Abstract
Neonatal gene therapy is a promising strategy for treating a number of congenital diseases diagnosed shortly after birth as expression of therapeutic proteins during postnatal life may limit the pathologic consequences and result in a potential "cure." Hemophilia A is often complicated by the development of antibodies to recombinant protein resulting in treatment failure. Neonatal administration of vectors may avoid inhibitory antibody formation to factor VIII (FVIII) by taking advantage of immune immaturity. A helper-dependent adenoviral vector expressing human factor VIII was administered i.v. to neonatal hemophilia A knockout mice. Three days later, mice produced high levels of FVIII. Levels declined rapidly with animal growth to 5 wk of age with stable factor VIII expression thereafter to >1 y of age. Decline in factor VIII expression was not related to cell-mediated or humoral responses with lack of development of antibodies to capsid or human factor VIII proteins. Subsequent readministration and augmentation of expression was possible as operational tolerance was established to factor VIII without development of inhibitors; however, protective immunity to adenovirus remained.Keywords
This publication has 65 references indexed in Scilit:
- Lymphomagenesis in SCID-X1 Mice Following Lentivirus-mediated Phenotype Correction Independent of Insertional Mutagenesis and γc OverexpressionMolecular Therapy, 2010
- RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMNNature Biotechnology, 2010
- Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reductionGene Therapy, 2009
- Inhibitors of Factor VIII in Black Patients with HemophiliaThe New England Journal of Medicine, 2009
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1JCI Insight, 2008
- Correction of Murine Hemophilia A and Immunological Differences of Factor VIII Variants Delivered by Helper-dependent Adenoviral VectorsMolecular Therapy, 2007
- Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:cThrombosis and Haemostasis, 2007
- Fetal and neonatal gene therapy: benefits and pitfallsGene Therapy, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- Long Term Correction of Bilirubin-UDP-glucuronosyltransferase Deficiency in Gunn Rats by Administration of a Recombinant Adenovirus during the Neonatal PeriodPublished by Elsevier BV ,1996